請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/82142完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 廖憶純(Yi-Chun Liao) | |
| dc.contributor.author | I-Shiuan Li | en |
| dc.contributor.author | 李怡萱 | zh_TW |
| dc.date.accessioned | 2022-11-25T05:36:46Z | - |
| dc.date.available | 2026-10-01 | |
| dc.date.copyright | 2021-10-21 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-10-04 | |
| dc.identifier.citation | 1. Torres, J., et al., Crohn's disease. Lancet, 2017. 389(10080): p. 1741-1755. 2. Roda, G., et al., Crohn's disease. Nat Rev Dis Primers, 2020. 6(1): p. 22. 3. Peyrin-Biroulet, L., et al., Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis, 2011. 17(1): p. 471-8. 4. Vavricka, S.R., et al., Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol, 2011. 106(1): p. 110-9. 5. Zheng, K., et al., Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitis. PLoS One, 2015. 10(4): p. e0124211. 6. Lennard-Jones, J.E., Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl, 1989. 170: p. 2-6; discussion 16-9. 7. Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54 e42; quiz e30. 8. Prideaux, L., et al., Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol, 2012. 27(8): p. 1266-80. 9. Kuo, C.J., et al., The Trend of Inflammatory Bowel Diseases in Taiwan: A Population-Based Study. Dig Dis Sci, 2015. 60(8): p. 2454-62. 10. Yen, H.H., et al., Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. Intest Res, 2019. 17(1): p. 54-62. 11. Thia, K.T., et al., An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol, 2008. 103(12): p. 3167-82. 12. Moller, F.T., et al., Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. Am J Gastroenterol, 2015. 110(4): p. 564-71. 13. Kim, H.J., et al., Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study in South Korea. Clin Gastroenterol Hepatol, 2020. 14. Cabre, E. and E. Domenech, Impact of environmental and dietary factors on the course of inflammatory bowel disease. World J Gastroenterol, 2012. 18(29): p. 3814-22. 15. Mahid, S.S., et al., Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc, 2006. 81(11): p. 1462-71. 16. Ananthakrishnan, A.N., et al., Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut, 2014. 63(5): p. 776-84. 17. Pullan, R.D., et al., Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut, 1994. 35(3): p. 353-9. 18. Parikh, K., et al., Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature, 2019. 567(7746): p. 49-55. 19. Furey, T.S., P. Sethupathy, and S.Z. Sheikh, Redefining the IBDs using genome-scale molecular phenotyping. Nat Rev Gastroenterol Hepatol, 2019. 16(5): p. 296-311. 20. Yun, J., C.T. Xu, and B.R. Pan, Epidemiology and gene markers of ulcerative colitis in the Chinese. World J Gastroenterol, 2009. 15(7): p. 788-803. 21. Michail, S., G. Bultron, and R.W. Depaolo, Genetic variants associated with Crohn's disease. Appl Clin Genet, 2013. 6: p. 25-32. 22. Sales-Campos, H., et al., Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res, 2015. 48(2): p. 96-107. 23. Jeong, D.Y., et al., Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev, 2019. 18(5): p. 439-454. 24. Ardizzone, S., et al., Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol, 2010. 3(1): p. 31-42. 25. Egan, L.J., et al., Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem, 1999. 274(37): p. 26448-53. 26. Weber, C.K., et al., Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology, 2000. 119(5): p. 1209-18. 27. Allgayer, H. and W. Kruis, Aminosalicylates: potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol, 2002. 37(2): p. 125-31. 28. Oka, A. and R.B. Sartor, Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Dig Dis Sci, 2020. 65(3): p. 757-788. 29. Moura, F.A., et al., Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol, 2015. 6: p. 617-639. 30. Li, H., et al., Synergic interactions between polyphenols and gut microbiota in mitigating inflammatory bowel diseases. Food Funct, 2020. 11(6): p. 4878-4891. 31. Saber, S., et al., Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NFkappaB and Nrf-2/HO-1 signaling crosstalk. Toxicol Appl Pharmacol, 2019. 364: p. 120-132. 32. Beloborodova, N., et al., Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci, 2012. 19: p. 89. 33. Khare, T., et al., Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel Disease. Int J Mol Sci, 2020. 21(11). 34. Zhang, M., et al., Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials, 2016. 101: p. 321-40. 35. Davatgaran-Taghipour, Y., et al., Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int J Nanomedicine, 2017. 12: p. 2689-2702. 36. Liu, H., et al., Polyphenols contents and antioxidant capacity of 68 Chinese herbals suitable for medical or food uses. Food Research International - FOOD RES INT, 2008. 41: p. 363-370. 37. Hsieh, S.C., et al., The methanol-ethyl acetate partitioned fraction from Chinese olive fruits inhibits cancer cell proliferation and tumor growth by promoting apoptosis through the suppression of the NF-κB signaling pathway. Food Funct, 2016. 7(12): p. 4797-4803. 38. Kuo, C.T., et al., Antioxidant and antiglycation properties of different solvent extracts from Chinese olive (Canarium album L.) fruit. Asian Pac J Trop Med, 2015. 8(12): p. 1013-1021. 39. Liu, Q., et al., Canarium album extract restrains lipid excessive accumulation in hepatocarcinoma cells. Int. J. Clin. Exp. Med, 2016. 9: p. 17509-17518. 40. Yeh, Y.T., et al., Chinese olive extract ameliorates hepatic lipid accumulation in vitro and in vivo by regulating lipid metabolism. Sci Rep, 2018. 8(1): p. 1057. 41. Zhang, N.-N., et al., Effect of A Polyphenol-Rich Canarium album Extract on the Composition of the Gut Microbiota of Mice Fed a High-Fat Diet. Molecules (Basel, Switzerland), 2018. 23(9): p. 2188. 42. Yeh, Y.T., A.N. Chiang, and S.C. Hsieh, Chinese Olive (Canarium album L.) Fruit Extract Attenuates Metabolic Dysfunction in Diabetic Rats. Nutrients, 2017. 9(10). 43. Kao, Y.-H., et al., Study on Mechanisms Underlying the Preventive Effects of Canarium album L. ethanol Extract on Modulation of Hyperglycemia and Hypercholesterolemia in Diabetic Rats. Journal of Food and Nutrition Research, 2021. 6(4): p. 261-270. 44. Zhang, L.L. and Y.M. Lin, Tannins from Canarium album with potent antioxidant activity. J Zhejiang Univ Sci B, 2008. 9(5): p. 407-15. 45. Kuo, C.-T., et al., Antioxidant and antiglycation properties of different solvent extracts from Chinese olive (Canarium album L.) fruit. Asian Pacific Journal of Tropical Medicine, 2015. 8(12): p. 1013-1021. 46. Tamai, M., et al., New hepatoprotective triterpenes from Canarium album. Planta Med, 1989. 55(1): p. 44-7. 47. He, Z., et al., Identification of a new phenolic compound from Chinese olive (Canarium album L.) fruit. European Food Research and Technology, 2009. 228(3): p. 339-343. 48. he, Z. and W. Xia, Analysis of phenolic compounds in chinese olive (Canarium album L.) fruit by RPHPLC-DAD-ESI-MS. Food Chemistry, 2007. 105: p. 1307-1311. 49. Yeh, Y.T., et al., Chinese olive (Canarium album L.) fruit regulates glucose utilization by activating AMP-activated protein kinase. Faseb j, 2020. 34(6): p. 7866-7884. 50. Kuo, C.L., et al., Gallic acid inhibits migration and invasion of SCC-4 human oral cancer cells through actions of NF-κB, Ras and matrix metalloproteinase-2 and -9. Oncol Rep, 2014. 32(1): p. 355-61. 51. Khan, M.K., I.A. Ansari, and M.S. Khan, Dietary phytochemicals as potent chemotherapeutic agents against breast cancer: Inhibition of NF-κB pathway via molecular interactions in rel homology domain of its precursor protein p105. Pharmacogn Mag, 2013. 9(33): p. 51-7. 52. Wang, C.H., et al., Establishment of reporter platforms capable of detecting NF-κB mediated immuno-modulatory activity. J Agric Food Chem, 2013. 61(51): p. 12582-7. 53. Scheiffele, F. and I.J. Fuss, Induction of TNBS colitis in mice. Curr Protoc Immunol, 2002. Chapter 15: p. Unit 15.19. 54. Almeida Cde, S., et al., Crotoxin from Crotalus durissus terrificus is able to down-modulate the acute intestinal inflammation in mice. PLoS One, 2015. 10(4): p. e0121427. 55. Alex, P., et al., Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis, 2009. 15(3): p. 341-52. 56. Wright, C.E., D.D. Rees, and S. Moncada, Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res, 1992. 26(1): p. 48-57. 57. Tanabe, T. and N. Tohnai, Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat, 2002. 68-69: p. 95-114. 58. Surh, Y.J., et al., Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res, 2001. 480-481: p. 243-68. 59. Shin, S.Y., et al., γ-Oryzanol suppresses COX-2 expression by inhibiting reactive oxygen species-mediated Erk1/2 and Egr-1 signaling in LPS-stimulated RAW264.7 macrophages. Biochem Biophys Res Commun, 2017. 491(2): p. 486-492. 60. Waseem, T., et al., Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery, 2008. 143(3): p. 334-42. 61. Papadakis, K.A. and S.R. Targan, Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med, 2000. 51: p. 289-98. 62. Wang, C.-H., et al., Establishment of Reporter Platforms Capable of Detecting NF-κB Mediated Immuno-Modulatory Activity. Journal of Agricultural and Food Chemistry, 2013. 61(51): p. 12582-12587. 63. Kuo, Y.H., et al., Identification and Structural Elucidation of Anti-Inflammatory Compounds from Chinese Olive (Canarium Album L.) Fruit Extracts. Foods, 2019. 8(10). 64. Kumar, R.P. and A. Abraham, Inhibition of LPS induced pro-inflammatory responses in RAW 264.7 macrophage cells by PVP-coated naringenin nanoparticle via down regulation of NF-κB/P38MAPK mediated stress signaling. Pharmacol Rep, 2017. 69(5): p. 908-915. 65. Wang, J. and G. Mazza, Effects of anthocyanins and other phenolic compounds on the production of tumor necrosis factor alpha in LPS/IFN-gamma-activated RAW 264.7 macrophages. J Agric Food Chem, 2002. 50(15): p. 4183-9. 66. Gabay, C., Interleukin-6 and chronic inflammation. Arthritis Res Ther, 2006. 8 Suppl 2(Suppl 2): p. S3. 67. Vazquez-Torres, A., et al., Analysis of nitric oxide-dependent antimicrobial actions in macrophages and mice. Methods Enzymol, 2008. 437: p. 521-38. 68. Chung, H.T., et al., Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun, 2001. 282(5): p. 1075-9. 69. Taira, J., H. Nanbu, and K. Ueda, Nitric oxide-scavenging compounds in Agrimonia pilosa Ledeb on LPS-induced RAW264.7 macrophages. Food Chemistry, 2009. 115(4): p. 1221-1227. 70. Yi, J., et al., Dclk1 in tuft cells promotes inflammation-driven epithelial restitution and mitigates chronic colitis. Cell Death Differ, 2019. 26(9): p. 1656-1669. 71. Birchenough, G.M., et al., New developments in goblet cell mucus secretion and function. Mucosal Immunol, 2015. 8(4): p. 712-9. 72. Wang, X., F. Fan, and Q. Cao, Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption. Mol Med Rep, 2016. 14(2): p. 1173-9. 73. Sumagin, R. and C.A. Parkos, Epithelial adhesion molecules and the regulation of intestinal homeostasis during neutrophil transepithelial migration. Tissue Barriers, 2015. 3(1-2): p. e969100. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/82142 | - |
| dc.description.abstract | "發炎性腸道疾病是指消化道的慢性發炎疾病。主要分為潰瘍性結腸炎（UC）和克隆氏症（CD）。發炎性腸道疾病的發病率在亞洲持續增加，但發病的根本原因仍不清楚。目前最常使用的治療藥物有抗生素，例如：5-ASA，更嚴重的患者會使用生物製劑，例如：TNFα 的抑製劑英利昔單抗（Infliximab）。然而，長期使用這些藥物可能造成嚴重的副作用，因此仍迫切需要探究可以有效緩解發炎性腸道疾病且降低副作用的新療法。在本篇研究中，我們評估中國橄欖（Canarium album L.）是否具有可以緩解發炎性腸道疾病的潛力。由於在過去的研究中，我們已經發現中國橄欖的乙酸乙酯層萃取物（在本文中稱為COE）具有抗發炎的特性，在本研究中，我們首先使用 RAW264.7 小鼠巨噬細胞的平台來再次確認 COE 的抗發炎能力。我們觀察了幾種促炎介質的表現量，包含一氧化氮 (NO)、誘導型一氧化氮合成酶 (iNOS)、環氧合酶-2 (COX-2)、TNFα、IL-1β和 IL-6。冷光素酶檢測法的結果表明，與脂多醣（LPS）誘導組相比，以400 mg/L濃度的COE處理可顯著抑制iNOS啟動子的活性。此外，亞硝酸鹽檢測試驗的結果表明，濃度為 100、200、400 和 800 mg/L的COE 均能顯著抑制 LPS 誘導產生的 NO含量。 COE對LPS誘導的iNOS和COX-2蛋白質的表現量也有抑制作用。除此之外，我們也發現COE可以抑制RAW264.7細胞中促炎細胞因子的mRNA表現量，包含IL-1β和 IL-6。這些細胞實驗的發現促使我們更進一步研究 COE 對 2,4,6-三硝基苯磺酸（TNBS）誘導的急性克隆氏症模式小鼠的改善作用。在TNBS誘導的結腸炎組中，可觀察到疾病活動指數（DAI）相較於對照組有顯著的上升，然而COE治療組與結腸炎組之間無顯著差異。另一方面，與結腸炎組相比，治療組的組織學活性指數（HAI）則有顯著的降低，表明 COE 降低了結腸組織的發炎反應和上皮損傷的嚴重程度。我們還分析了 TNFα、IL-1β和 IL-6 在結腸組織中和血清中的表現量。與結腸炎組相比，治療組在近端結腸組織中的TNF-α 和IL-1β 的mRNA表現量均降低。儘管COE沒有降低IL-6在結腸組織中的mRNA表現量，但IL-6在血清中的濃度則在治療組中有所降低，甚至低於對照組。此外，COE 也降低了結腸組織中的 COX-2 蛋白質表現量。總結來說，我們的研究證實了中國橄欖萃取物表現出抗發炎的能力，並具有改善 TNBS 誘導結腸炎小鼠發炎症狀的潛力，表明 COE 可能作為預防和治療發炎性腸道疾病的天然療法。未來我們將進一步評估 COE 和現有治療發炎性腸道疾病的生物製劑（如Infliximab）之協同治療是否有更好的療效。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-25T05:36:46Z (GMT). No. of bitstreams: 1 U0001-0110202101523700.pdf: 11110059 bytes, checksum: d6004a83f279a29f4cdfc3979f1cd3ef (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | Abstract vii 1. Introduction 1 1.1 Inflammatory bowel disease 1 1.1.1 Crohn’s disease and ulcerative colitis 1 1.1.2 Epidemiology 2 1.1.3 Pathophysiology 3 1.1.4 Current treatment 4 1.1.5 Alternative or complementary therapy to IBD 5 1.2 Chinese Olive (Canarium album L.) 6 1.2.1 Previous studies of Chinese olive 6 1.2.2 The methanol-ethyl acetate partitioned fraction of Chinese olive 7 1.3 Aims of this study 8 2. Materials and Methods 9 2.1 Preparation of Chinese olive fruit extract 9 2.2 Cell culture 9 2.3 Cell Subculture 10 2.4 Cell counting 10 2.5 Water-Soluble Tetrazolium 1 (WST-1) Cell Viability Assay 11 2.6 Luciferase assay 11 2.7 RNA analysis 12 2.7.1 Preparation and quantification of cell RNA extract 12 2.7.2 Preparation and quantification of tissue RNA extract 12 2.7.3 Reverse transcription 12 2.7.4 Quantitative reverse transcription polymerase chain reaction 12 2.8 Protein analysis 14 2.8.1 Preparation and quantification of cell protein lysate 14 2.8.2 Preparation and quantification of tissue protein lysate 14 2.8.3 SDS-PAGE 15 2.8.4 Western blotting 15 2.9 Assessment of NO production (Griess assay) 16 2.10 Animals 17 2.11 Establishment of TNBS-induced colitis model 18 2.12 Evaluation of DAI score 19 2.13 Histological analysis 19 2.14 Enzyme-linked immune-sorbent assay (ELISA) 20 3. Results 21 3.1 Effect of COE on RAW264.7 cell viability 21 3.2 Effects of COE on the Promoter Activity of iNOS Gene and the Production of NO in LPS-Induced RAW264.7 Cells. 21 3.3 Effects of COE on the Protein Expression of iNOS and COX-2 in LPS-Induced RAW264.7 Cells. 22 3.4 Effects of COE on the mRNA Expression of Pro-inflammatory Cytokines in LPS-Induced RAW264.7 Cells. 23 3.5 Effects of COE on the Colitis Symptoms in TNBS-Induced Colitis Mice. 24 3.6 Effects of COE on the Histopathological Change in TNBS-Induced Colitis Mice. 25 3.7 Effects of COE on the Expression of Pro-inflammatory Cytokines in TNBS-Induced Colitis Mice. 27 3.8 Effects of COE on the Protein Expression of COX-2 in TNBS-Induced Colitis Mice. 28 4. Discussions and Future Perspectives 29 5. References 37 6. Figures 45 7. Supplementary 64 | |
| dc.language.iso | en | |
| dc.subject | 促炎介質 | zh_TW |
| dc.subject | 發炎性腸道疾病 | zh_TW |
| dc.subject | 克隆氏症 | zh_TW |
| dc.subject | 中國橄欖 | zh_TW |
| dc.subject | 抗發炎 | zh_TW |
| dc.subject | RAW264.7 | zh_TW |
| dc.subject | TNBS模式鼠 | zh_TW |
| dc.subject | Inflammatory bowel disease | en |
| dc.subject | pro-inflammatory cytokines | en |
| dc.subject | TNBS-induced mice | en |
| dc.subject | RAW264.7 | en |
| dc.subject | anti-inflammatory | en |
| dc.subject | Chinese olive | en |
| dc.subject | Crohn’s disease | en |
| dc.title | 探討中國橄欖萃取物對TNBS誘導腸炎小鼠的改善功效 | zh_TW |
| dc.title | Effects of Chinese Olive (Canarium album L.) Fruit Extract on Attenuating TNBS-Induced Colitis in Mice | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃楓婷(Hsin-Tsai Liu),謝淑貞(Chih-Yang Tseng),賴韻如 | |
| dc.subject.keyword | 發炎性腸道疾病,克隆氏症,中國橄欖,抗發炎,RAW264.7,TNBS模式鼠,促炎介質, | zh_TW |
| dc.subject.keyword | Inflammatory bowel disease,Crohn’s disease,Chinese olive,anti-inflammatory,RAW264.7,TNBS-induced mice,pro-inflammatory cytokines, | en |
| dc.relation.page | 65 | |
| dc.identifier.doi | 10.6342/NTU202103485 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-10-04 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| dc.date.embargo-lift | 2026-10-14 | - |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0110202101523700.pdf 未授權公開取用 | 10.85 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。